WeightWatchers stock price skyrockets on news that it will offer a compounded GLP-1 weight-loss drug like Wegovy
The embattled diet brand said it is adding a compounded weight-loss drug in accordance with FDA rules and manufacturing standards.
WeightWatchers to offer compounded version of Wegovy weight-loss drug
WeightWatchers said on Tuesday it would offer a compounded version of Novo Nordisk's popular obesity drug Wegovy as part of its weight-management programs.
WeightWatchers cashes in on popularity of weight loss drugs with compounded semaglutide
WW International (NASDAQ:WW), more commonly known as WeightWatchers, will now offer compounded semaglutide to its WeightWatchers Clinic members, expanding the accessibility of popular weight loss medications to its members at a more affordable price.
WeightWatchers is getting in on the off-brand weight loss drug game — and selling them cheap
WeightWatchers (WW) announced Tuesday that it is now offering off-brand weight loss drugs for one of the cheapest prices in the industry.
WeightWatchers CEO Sima Sistani out in abrupt exit, embraced weight loss drugs
WeightWatchers announced Friday that CEO Sima Sistani is no longer at the company, and independent board member Tara Comonte has stepped in to serve as interim CEO.
WeightWatchers is struggling in the weight loss drug era — and now the CEO is out
International said Friday that CEO Sima Sistani is stepping down immediately. She will be replaced by Tara Comonte, a board member and the former CEO of Shake Shack (SHAK), who was appointed as interim chief executive effective immediately.
WeightWatchers’ stock soars after adding compounded GLP-1 treatment to its offering
Shares of WW International Inc., known as WeightWatchers, soared 18% Tuesday, after the weight-management company announced the addition of compounded GLP-1 obesity treatments to its offering. The new offering starts at $129.
WeightWatchers to offer compounded weight-loss drugs
WeightWatchers will begin selling compounded alternatives to certain weight-loss drugs that are experiencing shortages. Why it matters: Federal law allows companies to sell compounded versions of drugs that are on the FDA's shortages list — which has led to a surge of copycats to the newly popular class of GLP-1 injections.
WeightWatchers offers version of Ozempic, despite FDA concerns
High demand has created a market for compounded versions of the drug best known as Ozemic or Wegovy, but doctors and the FDA say those versions come with risks.
WeightWatchers Is Offering Knockoff Wegovy. The Market Is Already Crowded.
The compounding pharmacies that supply knockoff Wegovy can only legally make it as long as it remains on the Food and Drug ...
Weight Watchers Stock Rises 38% On Plan To Sell Obesity Drugs
Shares of Weight Watchers parent company WW International (WW) rose nearly 40% after the company announced plans to begin ...
Hosted on MSN1d
WeightWatchers (NASDAQ:WW) Stock Jumps 40% on Plan to Sell Obesity Medications
Shares of WeightWatchers parent company WW International ($WW) have rocketed 40% higher on news that the company plans to ...
WeightWatchers extends gains as analysts cite boost from compounded Wegovy version
Shares in WeightWatchers surged by nearly 38% in extended hours trading on Wednesday, pointing to an extension in sharp gians ...
New York Post13d
WeightWatchers CEO suddenly quits after push to embrace weight-loss drugs like Ozempic, Wegovy
WeightWatchers CEO Sima Sistani abruptly stepped down Friday after a two-year stint that included a controversial embrace of weight-loss drugs like Ozempic and Wegovy. Sistani pushed the 61-year ...
WeightWatchers stock soars, but its cheap Wegovy knockoff 'is not a sustainable long-term business model'
WW International, known as WeightWatchers, saw its stock soar on new of its new compounded GLP-1 offering. But analysts say ...
devdiscourse2d
WeightWatchers Launches Compounded Novo Nordisk Drug Amid Health Innovations
Current health news highlights WeightWatchers offering a compound version of Novo Nordisk's obesity drug, Danco seeking FDA ...